This single arm study will assess the safety of NeoRecormon in the correction of anemia in patients with chronic hepatitis C who are being treated with Pegylated interferon + ribavirin combination therapy. Patients will receive NeoRecormon at a starting dose of 30,000 IU s.c. which will be adjusted as required to maintain a target Hb of 11-13g/dL. The anticipated time on study treatment is 1 year, and the target sample size is 100-500 individuals.

Inclusion Criteria:

• adult patients, >=18 years of age;
• chronic hepatitis C;
• quantifiable serum HCV RNA;
• Pegylated interferon + ribavirin treatment started <6 months before study;
• Hb <10g/dL.

Exclusion Criteria:

• treatment with ESA during preceding 12 weeks;
• poorly controlled hypertension;
• history of cancer, except for basal cell cancer and cervical cancer in situ.